|
1
|
Serov SF, Scully R and Sobin LH:
Histologic typing of ovarian tumors. Geneva: World Health
Organization; 1973
|
|
2
|
Mabuchi S, Sugiyama T and Kimura T: Clear
cell carcinoma of the ovary: Molecular insights and future
therapeutic perspectives. J Gynecol Oncol. 27:e312016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crotzer DR, Sun CC, Coleman RL, Wolf JK,
Levenback CF and Gershenson DM: Lack of effective systemic therapy
for recurrent clear cell carcinoma of the ovary. Gynecol Oncol.
105:404–408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takano M, Sugiyama T, Yaegashi N, Sakuma
M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, et al:
Low response rate of second-line chemotherapy for recurrent or
refractory clear cell carcinoma of the ovary: A retrospective Japan
Clear Cell Carcinoma Study. Int J Gynecol Cancer. 18:937–942. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varier RA and Timmers HT: Histone lysine
methylation and demethylation pathways in cancer. Biochim Biophys
Acta. 1815:75–89. 2011.PubMed/NCBI
|
|
6
|
Hamamoto R, Saloura V and Nakamura Y:
Critical roles of non-histone protein lysine methylation in human
tumorigenesis. Nat Rev Cancer. 15:110–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sone K, Piao L, Nakakido M, Ueda K,
Jenuwein T, Nakamura Y and Hamamoto R: Critical role of lysine 134
methylation on histone H2AX for gamma-H2AX production and DNA
repair. Nat Commun. 5:56912014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bitler BG, Aird KM, Garipov A, Li H,
Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM,
Conejo-Garcia JR, et al: Synthetic lethality by targeting EZH2
methyltransferase activity in ARID1A-mutated cancers. Nat Med.
21:231–238. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kojima M, Sone K, Oda K, Hamamoto R,
Kaneko S, Oki S, Kukita A, Machino H, Honjoh H, Kawata Y, et al:
The histone methyltransferase WHSC1 is regulated by EZH2 and is
important for ovarian clear cell carcinoma cell proliferation. BMC
Cancer. 19:4552019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oki S, Sone K, Oda K, Hamamoto R, Ikemura
M, Maeda D, Takeuchi M, Tanikawa M, Mori-Uchino M, Nagasaka K, et
al: Oncogenic histone methyltransferase EZH2: A novel prognostic
marker with therapeutic potential in endometrial cancer.
Oncotarget. 8:40402–40411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brown MA, Sims RJ III, Gottlieb PD and
Tucker PW: Identification and characterization of Smyd2: A split
SET/MYND domain-containing histone H3 lysine 36-specific
methyltransferase that interacts with the Sin3 histone deacetylase
complex. Mol Cancer. 5:262006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang J, Perez-Burgos L, Placek BJ,
Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T
and Berger SL: Repression of p53 activity by Smyd2-mediated
methylation. Nature. 444:629–632. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho HS, Hayami S, Toyokawa G, Maejima K,
Yamane Y, Suzuki T, Dohmae N, Kogure M, Kang D, Neal DE, et al: RB1
methylation by SMYD2 enhances cell cycle progression through an
increase of RB1 phosphorylation. Neoplasia. 14:476–486. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Piao L, Kang D, Suzuki T, Masuda A, Dohmae
N, Nakamura Y and Hamamoto R: The histone methyltransferase SMYD2
methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in
cancer cells. Neoplasia. 16:257–264, 264.e2. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamamoto R, Toyokawa G, Nakakido M, Ueda K
and Nakamura Y: SMYD2-dependent HSP90 methylation promotes cancer
cell proliferation by regulating the chaperone complex formation.
Cancer Lett. 351:126–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang R, Deng X, Yoshioka Y, Vougiouklakis
T, Park JH, Suzuki T, Dohmae N, Ueda K, Hamamoto R and Nakamura Y:
Effects of SMYD2-mediated EML4-ALK methylation on the signaling
pathway and growth in non-small-cell lung cancer cells. Cancer Sci.
108:1203–1209. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng X, Hamamoto R, Vougiouklakis T, Wang
R, Yoshioka Y, Suzuki T, Dohmae N, Matsuo Y, Park JH and Nakamura
Y: Critical roles of SMYD2-mediated β-catenin methylation for
nuclear translocation and activation of Wnt signaling. Oncotarget.
8:55837–55847. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kukita A, Sone K, Oda K, Hamamoto R,
Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, et al:
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in
combination with poly ADP ribose polymerase inhibitor has
therapeutic potential against high-grade serous ovarian carcinomas.
Biochem Biophys Res Commun. 513:340–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yokogi S, Tsubota T, Kanki K, Azumi J,
Itaba N, Oka H, Morimoto M, Ryoke K and Shiota G: Wnt/Beta-catenin
signal inhibitor HC-1 sensitizes oral squamous cell carcinoma cells
to 5-fluorouracil through reduction of CD44-positive population.
Yonago Acta Med. 59:93–99. 2016.PubMed/NCBI
|
|
21
|
Lyles RH, Poindexter C, Evans A, Brown M
and Cooper CR: Nonlinear model-based estimates of IC(50) for
studies involving continuous therapeutic dose-response data.
Contemp Clin Trials. 29:878–886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Price C, Gill S, Ho ZV, Davidson SM,
Merkel E, McFarland JM, Leung L, Tang A, Kost-Alimova M, Tsherniak
A, et al: Genome-wide interrogation of human cancers identifies
EGLN1 dependency in clear cell ovarian cancers. Cancer Res.
79:2564–2579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Anglesio MS, Wiegand KC, Melnyk N, Chow C,
Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR,
et al: Type-specific cell line models for type-specific ovarian
cancer research. PLoS One. 8:e721622013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh PK: Histone methyl transferases: A
class of epigenetic opportunities to counter uncontrolled cell
proliferation. Eur J Med Chem. 166:351–368. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abu-Farha M, Lambert JP, Al-Madhoun AS,
Elisma F, Skerjanc IS and Figeys D: The tale of two domains:
Proteomics and genomics analysis of SMYD2, a new histone
methyltransferase. Mol Cell Proteomics. 7:560–572. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Komatsu S, Ichikawa D, Hirajima S, Nagata
H, Nishimura Y, Kawaguchi T, Miyamae M, Okajima W, Ohashi T,
Konishi H, et al: Overexpression of SMYD2 contributes to malignant
outcome in gastric cancer. Br J Cancer. 112:357–364. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li LX, Zhou JX, Calvet JP, Godwin AK,
Jensen RA and Li X: Lysine methyltransferase SMYD2 promotes triple
negative breast cancer progression. Cell Death Dis. 9:3262018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sakamoto LH, Andrade RV, Felipe MS,
Motoyama AB and Pittella Silva F: SMYD2 is highly expressed in
pediatric acute lymphoblastic leukemia and constitutes a bad
prognostic factor. Leuk Res. 38:496–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun JJ, Li HL, Ma H, Shi Y, Yin LR and Guo
SJ: SMYD2 promotes cervical cancer growth by stimulating cell
proliferation. Cell Biosci. 9:752019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ,
Hung MH and Liu FS: p53 mutation is infrequent in clear cell
carcinoma of the ovary. Gynecol Oncol. 80:189–193. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Meng F, Liu X, Lin C, Xu L, Liu J, Zhang
P, Zhang X, Song J, Yan Y, Ren Z and Zhang Y: SMYD2 suppresses APC2
expression to activate the Wnt/β-catenin pathway and promotes
epithelial-mesenchymal transition in colorectal cancer. Am J Cancer
Res. 10:997–1011. 2020.PubMed/NCBI
|
|
32
|
Nguyen H, Allali-Hassani A, Antonysamy S,
Chang S, Chen LH, Curtis C, Emtage S, Fan L, Gheyi T, Li F, et al:
LLY-507, a cell-active, potent, and selective inhibitor of
protein-lysine methyltransferase SMYD2. J Biol Chem.
290:13641–13653. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cole AJ, Dwight T, Gill AJ, Dickson KA,
Zhu Y, Clarkson A, Gard GB, Maidens J, Valmadre S, Clifton-Bligh R
and Marsh DJ: Assessing mutant p53 in primary high-grade serous
ovarian cancer using immunohistochemistry and massively parallel
sequencing. Sci Rep. 6:261912016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ishibashi H, Takano M, Miyamoto M, Soyama
H, Matsuura H, Aoyama T, Yoshikawa T, Kato K, Tsuda H and Furuya K:
Role of endometriosis as a prognostic factor for post-progression
survival in ovarian clear cell carcinoma. Mol Clin Oncol.
7:1027–1031. 2017.PubMed/NCBI
|
